

FebriDx® Provides Clarity When It Matters Most

FebriDx is a rapid, point-of-care test that helps clinicians differentiate bacterial from non-bacterial acute respiratory infection (ARI) in 10 minutes using a simple fingerstick blood sample.

What Do NPV and PPV Mean—and Why Should You Care?

NPV | Negative Predictive Value

If the test says NON-BACTERIAL, how likely is it truly non-bacterial?

It tells you how confident you can be that a negative (non-bacterial) result is correct.

FebriDx NPV:

98.7%

to rule out bacterial infection*

In the U.S. clinical study:

374 of 379

patients with a non-bacterial result were truly non-bacterial.

Why it matters:

A non-bacterial result gives clinicians strong reassurance to consider withholding antibiotics when the clinical assessment agrees—supporting antimicrobial stewardship and better care.

PPV | Positive Predictive Value

If the test says BACTERIAL, how likely is it truly bacterial?

It tells you how much a positive (bacterial) result raises the likelihood of bacterial infection.

FebriDx PPV:

58.1%*

What this means:

When FebriDx indicates bacterial, the probability of bacterial infection increases.

Why it matters:

A bacterial result raises concern for bacterial infection and supports clinical decision-making, further evaluation and appropriate treatment. Interpret it in the context of signs and symptoms.

How FebriDx Changes Diagnostic Uncertainty

Using data from the U.S. clinical study (Bayesian analysis):

Before FebriDx

Example patient with an estimated 40% chance of bacterial infection

40%

FebriDx Non-Bacterial Result

Post-test probability drops to

5%

Helps rule out bacterial infection

FebriDx Bacterial Result

Post-test probability rises to

84%

Increases likelihood of bacterial infection

The Bottom Line

FebriDx delivers high NPV to confidently rule out bacterial infection and meaningful PPV to increase the likelihood of bacterial infection—helping clinicians make more confident decisions.

Reduce unnecessary antibiotic use | Improve patient care | Support antimicrobial stewardship

*FebriDx U.S. clinical study (n=520 evaluable patients): NPV 98.7% (374/379); PPV 58.1% (43/74). Refer to the Instructions for Use (PM-127) for complete performance data.

References:

1. FebriDx Bacterial / Non-Bacterial Assay, FDA 510(k) K230917 and K240787
2. FebriDx Bacterial / Non-Bacterial Point of Care Assay; Lumos Diagnostics Instructions for Use (PM-127)
3. Shapiro NI, Filbin MR, Hou PC, Kurz MC, Han JH, Aufderheide TP, et al. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting. JAMA Netw Open. 2022;5(10):e2234588. doi:10.1001/jamanetworkopen.2022.34588.
4. American Hospital Association: <https://www.aapc.com/codes/hcpcs-codes/0442U>



Fast. Simple. Actionable.

10-minute results. Fingerstick blood. Better decisions.